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Dear Editor,
Conquering the AIDS epidemic remains one of the most
challenging global health issues. Despite impressive
advances in combination antiretroviral therapy (cART) to
treat HIV, and substantial progress in the development of
prevention interventions, a protective vaccine has remained
elusive. Successful vaccination will require the immune
system to function better than it does in natural infection, in
which the infection invariably becomes chronic. However,
there are a very small number of patients termed “elite
controllers” who become infected but can control viremia,
with the preponderance of evidence pointing to CD8+ T cell
mediated immune control. The existence of such patients
implies that the human immune system, although not able
to eradicate infection, is potentially capable of durable
control of HIV-1 and prevention of HIV-associated disease
[reviewed in (Deeks and Walker, 2007; Walker and Yu,
2013)].
The beauty of Major Histocompatibility Complex (MHC)-
restriction in T cell immunity is that within a population, there
may always be individuals who bear particular MHC alleles,
able to present antigenic peptides derived from invading
pathogens for T cell receptors (TCRs) to recognize. This
ultimately gives rise to effective cellular immunity to control
chronic infection to save the species (Zinkernagel and
Doherty, 1997). This has been exempliﬁed by the global HIV-
1 epidemic. The above-mentioned “elite controllers” (as
opposed to progressors) are enriched in expression of cer-
tain “protective” class I Human Leukocyte Antigen (HLA)
alleles such as HLA-B*57/5801 subtypes and B*27. By
contrast, other persons who express so-called deleterious or
disease susceptible alleles, including HLA-B*18/53 are much
more likely to develop AIDS in the absence of cART (O’Brien
et al., 2001). Obviously, the differential peptide presentation
by HLA molecules is rooted in host MHC polymorphism.
Indeed, a genome-wide association study (GWAS) clearly
demonstrated that speciﬁc amino acid variations in the
peptide-binding groove are associated with host control of
HIV-1 infection (Pereyra et al., 2010). Therefore, unraveling
the molecular mechanism of host control of HIV-1 infection
by cellular immunity is extremely important for eventually
devising a strategy to eliminate the HIV-1 epidemic.
To begin to address the structural basis for Tcell mediated
control of HIV, we initiated a structural analysis of an
immunodominant CD8+ T cell epitope QW9 (QASQEVKNW,
p24gag residues 176–184) from HIV-1 bound to the restricting
HLA class I molecule B*5801. This epitope is of particular
interest because the conserved Gag protein forms the
essential capsid of HIV-1 (Zhao et al., 2013), with mutations
likely to impose a ﬁtness cost. In addition, QW9 can be
presented by a spectrum of HLA molecules for comparative
investigation (Buseyne et al., 2001; Buseyne et al., 1997;
Currier et al., 2005; Kloverpris et al., 2013). Here, we report
the ﬁrst crystal structures of HLA-B*5801, one of the most
HIV-protective HLA molecules, loaded with QW9 and its
natural variants QW9-S3T and QW9-E5D. All three struc-
tures are in a very similar crystal lattice and have two inde-
pendent molecules in one asymmetric unit. Fig. 1A is the
overall view of one of the QW9wt/HLA-B*5801 complexes in
crystal structure. The most interesting feature of these three
QW9/HLA-B*5801 complex structures is that the conforma-
tion of the middle portion of the bound peptide appears
varied (Fig. 1B), even between the two independent mole-
cules in the same crystal structure (Fig. 1C–E). It is not
uncommon to have a highly exposed residue at the center of
the presenting peptide on the HLA molecule to have its side
chain ﬂexible (Ladell et al., 2013). Our unique observation is
that among these six QW9/HLA complexes in three crystal
structures, the peptide residue K7 can be modeled outwards
in two cases (Fig. 1C for QW9wt-1 and Fig. 1D for QW9-
E5D-2), but buried inwards in another two cases (Fig. 1C for
QW9wt-2 and Fig. 1E for QW9-S3T-2). It should be
emphasized that despite the weak density of the long and
ﬂoppy side chain, the density for the main chain conforma-
tion and the Cα-Cβ direction of the K7 residue in Fig. 1C–E is
actually convincing enough for the assignment of its side
chain to be outwards (convex-shaped main chain in Fig. 1C
for QW9wt-1 and Fig. 1D for QW9-E5D-2) or inwards (con-
cave-shaped main chain in Fig. 1C for QW9wt-2 and Fig. 1E
for QW9-E5D-2).
The above structural data imply that unlike those
anchoring residues (W9 in QW9 as a typical example, see
Fig. 1B), the conformation of the central protruding residues,
K7 in particular, can actually be in a dynamic distribution.
This is probably because the whole protruding and mobile
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Figure 1. Structures of HLA-B*5801 complex with QW9 and its variants. (A) Overall view of the structure of QW9wt/HLA-B*5801.
The heavy chain is in green and the β2m domain is in cyan. The peptide QW9wt is in a yellow stick model. (B) Overlay of structures of
HLA-B*5801 loaded with wild-type QW9 and its variants, E5D and S3T. The front helix of HLA has been removed for clarity. (C–E)
The 2Fo-Fc difference maps for the bound peptide only. Shown here are peptides in six independent peptide/HLA-B*5801 complexes
of three crystal structures determined. The map is contoured at 0.9 σ level. Note that in Fig. D and E, the densities of QW9-E5D-1 and
QW9-S3T-1 are too weak to assign the long ﬂoppy side chain of K7. Only Ala is modeled instead. But their main chain conformations
are in convex shape, indicating that the ﬂexible side chain of K7 should point outwards. (F) The peptide-binding mode. Shown here is
the hydrogen-bonding network between peptide and HLA molecule for three representative structures. Hydrogen bonds are shown in
magenta dash lines. The magenta-colored balls are water molecules. HLA-B*5801 and its residues are in green and QW9 is in yellow
stick model. The important residues on QW9 and the variants are labeled in red. Again the front helix of HLA has been removed for
clarity.
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portion of the peptide (residues 6 to 8) gives the central K7
enough room for ﬂexibility. It is possible that during the
peptide loading process, the K7 residue can populate in
statistically different conformations, either ﬂuttering on the
peptide/HLA surface or embedded in the anchoring pocket of
the peptide-binding groove. Fig. 1C–E reﬂect what are cap-
tured in crystallization. It should be extremely interesting to
explore, in the future, how the dynamic features of this
peptide presentation by its restricting HLA molecule would
affect TCR recognition in the context of host control of HIV-1
infection.
The side chain of QW9 residue E5 is fully buried inside
the binding-groove, whereas residue S3 has its hydroxyl
group semi-exposed (Fig. 1B and 1F). Fig. 1F demonstrates
the QW9 speciﬁc binding mode in the peptide-binding
groove of HLA-B*5801 in three representative complexes.
Illustrated in this ﬁgure is a hydrogen-bonding network,
mediated by three conserved bound water molecules within
the groove. Comparing E5 in the structure of QW9wt/HLA-
B*5801 (Fig. 1F, left panel) with D5 in the structure of QW9-
E5D/HLA-B*5801 (Fig. 1F, middle panel), they both form
three hydrogen bonds in the binding groove. Apparently the
mutation of E5D does not change this binding pattern. The
mutation S3T is somewhat complicated. First of all, the
replacement of S3 to T3 does not noticeably change the
location the hydroxyl group, as shown in Fig. 1B. The “extra”
methyl group in QW9-S3T/HLA-B*5801 appears buried and
occupies a space near the bound water labeled as a blue
“W” in Fig. 1F (right panel). Comparing QW9wt/HLA-B*5801
(Fig. 1F, left panel) with QW9-S3T/HLA-B*5801 (Fig. 1F, right
panel), this “extra” methyl group does not seem to affect the
overall conformation of QW9/HLA-B*5801. In other words,
from a structural point of view, this “extra” methyl group in
S3T mutation does not seem to affect peptide presentation.
To sum up, we may have provided a structural rationale as to
why the naturally occurring E5D and S3T mutations would
not be expected to signiﬁcantly alter presentation and
recognition of epitope QW9 presented by HLA-B*5801
(Navis et al., 2007).
The genes coding for the heavy chain of HLA molecules
are highly polymorphic, which determines differential pep-
tide-presentation and TCR-recognition. The sequence vari-
ation between the HIV-1 “protective” allele HLA-B*5801 and
the deleterious allele HLA-B*5301 is eight residues (Fig. 2A),
which cluster on the α1-helical region of the heavy chain
shown in red in Fig. 2B. Fig. 2C and 2D demonstrate the
electrostatic potential surface representation for HLA-
B*5801 and HLA-B*5301, respectively. The view is down
from the TCR perspective, identical as the ribbon drawing of
HLA-B*5801 shown on Fig. 2B. As expected, the most
remarkable distinction between HLA-B*5801 and HLA-
B*5301 is at the top left region (shown as a circle in Fig. 2C
and 2D), corresponding to the sequence variable area
between HLA-B*5801 and HLA-B*5301 (the middle portion
difference between Fig. 2C and 2D was basically from the
bound peptides). This is the region that is contacted more by
the TCR complementary-determining region 1α (CDR1α
loop and also the CDR3α loop in a common pMHC/TCR
docking mode that was ﬁrst identiﬁed in 1998 (Teng et al.,
1998). This canonical binding mode is now seen in over 50
unique pMHC/TCR structures determined. The TCR will use
its germline-derived CDR1 and CDR2 loops to contact
genetically encoded polymorphic helical regions of MHC
molecule, and its V(D)J-recombined CDR3 loop in the center
of the complex for antigenic peptide recognition (Adams
et al., 2016).
In T cell immunity, MHC-restriction means that a TCR not
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Figure 2. Comparison between HLA-B*5801 and HLA-B*5301. (A) Sequence alignment of HLA-B*5801 and HLA-B*5301
(residues 61–72). Only eight residues differ between the two HLA molecules, and the residue R65 which contributes to the large
positive area in HLA-B*5801 is labeled with a star. (B) Ribbon drawing of HAL-B*5801 molecule viewing down the peptide-binding
groove from the TCR perspective. The distinct residues between HLA-B*5801 and HLA-B*5301 are in red region and cluster at the
α1-helical region of HLA molecule. The R65 is labeled and highlighted as sticker here. (C and D) Electrostatic potential surface
representation in the same view as in the ribbon drawing in B, for HLA-B*5801 and HLA-B*5301 (PDB: 1A1M), respectively. The red
color represents negative potential, the blue positive and the while color neutral. The most remarkable distinction between HLA-
B*5801 and HLA-B*5301 is highlighted as a circle.
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with the speciﬁc MHC molecule that presents this particular
peptide. The surface representation shown in Fig. 2C and/or
2D is the combined recognition surface, and the top left
corner difference between these two ﬁgures is what HLA-
B*5801 and HLA-B*5301 would differentially contribute to
stimulate disparate TCR molecules. It should be emphasized
that the exposed R65 in HLA-B*5801 (star-marked in Fig. 2A
and shown in Fig. 2B as a stick model) as opposed to Q65 in
HLA-B*5301 must be the important factor to give rise to the
large positive area in the region for HLA-B*5801. This area is
more likely to be contacted by CDR1α loop of a TCR, a
germline-derived structural element. Our immunological data
show that even sequences encoding the CDR3 loop were
signiﬁcantly more “germline-like’ used by controllers than
those used by progressors (Chen et al., 2012). The advan-
tage here may be related to a greater ability to recognize
mutational variants of an epitope. These should all contribute
to the host control of HIV-1 infection. It should also be
emphasized that more of the 8-residue differences between
HLA-B*5801 and HLA-B*5301 are involved in peptide-bind-
ing, which may not show up on the surface and hence not be
directly engaged in TCR contacts. These HLA residues
determine which peptide to present. While some distinct
HLA-alleles can present the identical peptide, the polymor-
phism may cause disparate HLA molecules to have different
peptide binding afﬁnities and binding kinetics, which will also
affect TCR recognition (Kloverpris et al., 2013).
In summary, we have reported the ﬁrst crystal structure of
HLA-B*5801 loaded with an immunodominant antigenic
peptide QW9 derived from HIV Gag protein. The unique
observation is that the central peptide residue K7 can
assume either a buried conformation in peptide-binding
groove or an exposed one. This dynamic may affect TCR
recognition. We have also provided a structural rationale for
why natural mutations of E5D and S3T can elicit a similar T
cell response as the wild type QW9 does. Comparing the
surface representation between HLA-B*5801 and HLA-
B*5301, we have discussed how these two HLA alleles may
contribute differently to host control of HIV-1 infection.
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